2. UroToday Home
  3. Trials in Progress

Trials in Progress

MEVPRO‑1 & MEVPRO‑2: Phase III Mevrometostat + Enzalutamide Studies in mCRPC

Trials in Progress
Videos

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT06551324
View Trial

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT06629779
View Trial
Physician-Scientist Commentaries
Peer-reviewed Abstract Supplemental Commentaries
Written by Evan Y. Yu, MD
Fred Hutchinson Cancer Center
The polycomb group protein enhancer of zeste homolog 2 (EZH2) has been a potentially promising target for prostate cancer dating back to an early Nature publication from the Chinnaiyan lab in 2002.1 In that manuscript, they showed that EZH2 is overexpressed in metastatic castration-resistant prostate cancer (mCRPC). Inhibition through genetic methods, in cell lines, decreased cell proliferation in vitro, and EZH2 expression correlated with worse prognosis, implicating a significant role of dysregulated EZH2 expression in prostate cancer progression.
Conference Coverage
Conference Highlights Written by Physician Scientists
Presented by Nobuaki Matsubara, MD
The 2026 ASCO GU cancers symposium held in San Francisco, CA, was host to the Poster Session A: Prostate Cancer. Dr. Nobuaki Matsubara presented Poster 195: Efficacy and safety of mevrometostat in combination with enzalutamide in patients with mCRPC: Data from a phase 1 study.
Presented by Nobuaki Matsubara, MD
The 2025 ASCO Annual Meeting held in Chicago, IL was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer. Dr. Nobuaki Matsubara presented Poster 5046: Safety and pharmacokinetics of mevrometostat in combination with enzalutamide in patients with mCRPC.
Presented by Neeraj Agarwal, MD, FASCO
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Neeraj Agarwal, MD, FASCO, presented the trial in progress Poster TPS5113: Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
Presented by Neal Shore, MD, FACS
The 2025 ASCO Annual Meeting held in Chicago, IL was host to a prostate, testicular, and penile cancers poster session. Dr. Neal Shore presented the ongoing MEVPRO-2 study, a randomized, phase III trial of mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve mCRPC patients.
Presented by Michael Schweizer, MD
At the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium, Michael Schweizer, MD, presented the results of a randomized dose-expansion study evaluating the combination of mevrometostat (PF-06821497), an EZH2 inhibitor, plus enzalutamide in mCRPC patients.
Presented by Neeraj Agarwal, MD, FASCO
At the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium, Neeraj Agarwal, MD, FASCO, presented the trial in progress poster 288: Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
Presented by Neeraj Agarwal, MD, FASCO
At the 2024 Society of Urologic Oncology (SUO) annual meeting, Neeraj Agarwal, MD, FASCO, presented the MEVPRO-1, a randomized phase III trial evaluating mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate.